ArticleBMC immunology2026
PHLDB1 and WDFY4 as dual-state biomarkers in SLE pathogenesis and lupus nephritis prediction.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesOur previous study confirmed systemic lupus erythematosus (SLE) associated with polymorphisms of PHLDB1 and WDFY4 genes. In this study, we investigatedthe clinical relevance of PHLDB1 and WDFY4 in SLE pathogenesis and their potential as biomarkers.
methodsA total of 634 SLE patients from Sichuan University West China Hospital and 400 age- and sex-matched healthy controls were included in this study. Serum PHLDB1 and WDFY4 of SLE patients and HCs were measured by ELISA, and the laboratory indicators were collected through the electronic medical record. LASSO, logistic regression, and random forest models for SLE diagnosis and LN prediction, including variables: age, sex, serum proteins (PHLDB1/WDFY4), genotypes, cytokines, and clinical markers.
resultsResults revealed elevated PHLDB1 in SLE patients compared to controls (1.61 vs. 1.48 ng/mL, P = 0.025), while paradoxically showing suppression in LN versus Non-LN patients (1.42 vs. 1.52 ng/mL, P = 0.031). WDFY4 specifically increased in LN (666.59 vs. 594.57 pg/mL, P < 0.001) without systemic SLE alterations. Machine learning models incorporating these biomarkers demonstrated diagnostic utility, with random forest achieving AUC 0.843 for SLE discrimination and AUC 0.990 for LN prediction. LN patients concurrently exhibited distinct immune dysregulation (reduced IL-6/IL-17 and elevated TNF-α/IL-18) and renal metabolic impairment. These findings position PHLDB1 as a systemic SLE biomarker and WDFY4 as a LN-specific blood indicator, showing promise for clinical subtyping applications. Further validation of these stratified biomarkers is warranted.
conclusionOur results confirm a correlation between the serum levels of PHLDB1 and the occurrence of SLE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.